| Literature DB >> 33440772 |
Jeffrey Zheng-Hsien Ko1, Sheeva Johnson1, Maneesh Dave1,2.
Abstract
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gut that can lead to severe gastrointestinal symptoms, malnutrition, and complications such as fistulas and cancer. Mesenchymal stem/stromal cells (MSCs) are being investigated as a novel therapy for IBD and have been demonstrated to be safe and effective for perianal fistulizing Crohn's disease (PFCD). This systematic review aims to present the most recent studies on the safety and efficacy of MSC therapy in IBD. A detailed search strategy of clinical trials on MSCs and IBD was performed on PubMed, with 32 studies selected for inclusion in this review. The newest studies on local MSC injection for PFCD continue to support long-term efficacy while maintaining a favorable safety profile. The evidence for systemic MSC infusion in luminal IBD remains mixed due to marked methodological heterogeneity and unclear safety profiles. Although further studies are needed to better establish the role of this novel treatment modality, MSCs are proving to be a very exciting addition to the limited therapies available for IBD.Entities:
Keywords: Crohn’s disease; efficacy; inflammatory bowel disease; mesenchymal stem/stromal cells; perianal fistula; safety; ulcerative colitis
Year: 2021 PMID： 33440772 PMCID： PMC7827559 DOI： 10.3390/biom11010082
Source DB: PubMed Journal: Biomolecules ISSN： 2218-273X